Revenue figures can be deceiving. Panacea Biotec generates roughly INR 265 crore (~$31 million) in annual revenue, a fraction of what India’s larger pharmaceutical companies earn in a single quarter. But this New Delhi-based company has supplied more than 10 billion polio immunisation doses worldwide, a number so large it becomes abstract until you consider what it means: Panacea’s vaccines have reached more human beings than the entire population of the planet. Founded in 1984 by Soshil Kumar Jain, a chemist’s son who built a WHO-prequalified vaccine operation from nothing, this is a company whose impact cannot be measured in rupees.
The number demands repetition because it resists comprehension: more than ten billion polio immunisation doses. Panacea Biotec is one of India’s few WHO-prequalified vaccine manufacturers, and its oral polio vaccine has been a cornerstone of the global eradication effort for decades. When UNICEF and the WHO needed affordable, reliable polio vaccine at a scale sufficient to immunise entire continents, Panacea was one of the companies that answered.
The WHO prequalification is not a courtesy title. It is a rigorous, multi-year evaluation process that examines manufacturing standards, quality management systems, cold chain integrity, and clinical evidence. Only a handful of Indian companies have achieved it for vaccines. Panacea holds WHO prequalification for multiple products: EasyFive (a pentavalent vaccine), Enivac-HB (hepatitis B), Ecovac-4 (quadrivalent), and Easyfour. These vaccines are supplied to more than 25 countries, primarily through UN procurement channels.
For a company generating $31 million in revenue, this reach is extraordinary. It reflects the economics of global public health: vaccines sold through international procurement at thin margins but enormous volumes, where the value created for humanity vastly exceeds the revenue captured by the manufacturer.
Soshil Kumar Jain began his career at his father’s chemist shop. There was nothing in that origin story that predicted what would follow: a company that would supply vaccines to a quarter of the world’s nations. Jain founded Panacea Drugs Private Limited in 1984, a modest pharmaceutical operation in New Delhi. The early years were unremarkable by the standards of India’s pharmaceutical industry, a small company making formulations for the domestic market.
The transformation came in 1993, when Panacea merged with Radicura Pharmaceuticals to form Panacea Biotec. The name change was not cosmetic. It signalled a strategic pivot toward biotechnology and vaccines, a bet that required entirely different capabilities than conventional pharmaceutical manufacturing: cold chain logistics, biological assay expertise, regulatory relationships with the WHO, and the patience to endure multi-year prequalification processes with no guarantee of success.
Two years later, in September 1995, the company listed on Indian stock exchanges under the ticker PANACEABIO. The IPO provided capital for the vaccine manufacturing infrastructure that would become the company’s defining capability. Jain led the company until his passing in 2022 at the age of 89, having seen his father’s chemist shop legacy transformed into a global vaccine supplier.
Vaccine manufacturing is categorically different from conventional pharmaceutical production. A tablet or capsule can survive ambient temperatures, rough handling, and months of shelf time. A vaccine is a biological product that must maintain strict cold chain integrity from the moment it leaves the production line until it reaches a child’s immune system. Any break in that chain renders the product useless or dangerous.
Panacea Biotec operates manufacturing facilities at Baddi in Himachal Pradesh, Lalru in Punjab, and Delhi. The Baddi facility carries US FDA approval, placing it among a select group of Indian vaccine plants that meet the most stringent regulatory standard in the world. Maintaining FDA approval for a vaccine facility is substantially more demanding than for a conventional drug plant: the biological complexity, sterility requirements, and batch-testing protocols are orders of magnitude more rigorous.
The company employs approximately 830 people, a workforce that is small by pharmaceutical industry standards but highly specialised. Vaccine manufacturing requires personnel with expertise in cell culture, fermentation, purification, lyophilisation, and quality control methodologies that most generic drug companies never encounter. Every employee at a vaccine facility operates in a regulated environment where a single deviation can invalidate an entire production batch.
In the pharmaceutical industry, companies are ranked by revenue. By that measure, Panacea Biotec is a minor player. Its $31 million in FY25 revenue would not register as a rounding error on the balance sheets of India’s top-ten pharma companies. Sun Pharma generates that much revenue in roughly two days.
But revenue is a measure of value captured, not value created. Panacea’s ten billion polio doses have contributed to one of the greatest public health achievements in human history: the near-eradication of poliomyelitis. In 1988, polio paralysed more than 350,000 children annually across 125 countries. Today, wild poliovirus remains endemic in only a handful of nations. That transformation required vaccines manufactured at a cost low enough for UNICEF to procure at scale, and at a quality high enough to satisfy WHO prequalification. Panacea delivered both.
The company’s WHO-prequalified portfolio, including EasyFive, Enivac-HB, Ecovac-4, and Easyfour, represents a capability that India’s pharmaceutical industry should regard as a national asset. WHO prequalification for vaccines is extraordinarily difficult to achieve and easy to lose. The fact that a company generating $31 million in revenue maintains it is a testament to the quality infrastructure that Soshil Kumar Jain built over four decades.
Sources: Panacea Biotec Limited Annual Reports and stock exchange filings. WHO Prequalification Programme vaccine product listings. US FDA facility registration data. UNICEF Supply Division vaccine procurement records.